株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

感染対策の世界市場:2020年~2024年

Infection Control Market by Type and Geography - Forecast and Analysis 2020-2024

発行 TechNavio (Infiniti Research Ltd.) 商品コード 917425
出版日 ページ情報 英文 155 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.68円で換算しております。
感染対策の世界市場:2020年~2024年 Infection Control Market by Type and Geography - Forecast and Analysis 2020-2024
出版日: 2019年11月19日 ページ情報: 英文 155 Pages
概要

世界の感染対策市場は、医療関連感染(HAI)の発生率の高さ、世界中での外科的処置の増加、高齢者人口の増加などが成長促進要因となり、予測期間中に4%以上のCAGRで拡大する見込みです。ただし、再処理された機器の安全性、抗感染治療におけるコンプライアンス違反、および感染予防薬の保管と輸送に伴う煩雑さに関する懸念などの要因が、予測期間中の感染対策業界の成長を妨げる可能性があります。

当レポートでは、世界の感染対策市場について調査分析し、市場規模および成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析
  • バリューチェーン分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2019年)
  • 市場規模および予測(2019年~2024年)
  • 市場の見通し

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 市場セグメンテーション:タイプ別

  • 市場セグメンテーション:タイプ別
  • タイプ別比較:市場規模および予測(2019年~2024年)
  • 治療薬
  • 非治療薬
  • 市場機会:タイプ別

第7章 顧客情勢

第8章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2019年~2024年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第11章 市場動向

  • 滅菌装置の技術的進歩
  • 感染症に関する意識の高まり
  • 輸血による感染拡大のリスクの増大

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競争シナリオ

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • 3M Co.
  • Astellas Pharma Inc.
  • Cantel Medical Corp.
  • Ecolab Inc.
  • Getinge AB
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Mylan NV
  • Pfizer Inc.
  • Sanofi

第14章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第15章 TECHNAVIOについて

図表

LIST OF EXHIBITS:

  • Exhibit 01: Vendors: Key offerings
  • Exhibit 02: Global healthcare market
  • Exhibit 03: Segments of global healthcare market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2019
  • Exhibit 08: Global market: Size and forecast 2019-2024 ($ billions)
  • Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
  • Exhibit 10: Five forces analysis 2019
  • Exhibit 11: Five forces analysis 2024
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2019
  • Exhibit 18: Type - Market share 2019-2024 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Therapeutic - Market size and forecast 2019-2024 ($ billions)
  • Exhibit 21: Therapeutic - Year-over-year growth 2020-2024 (%)
  • Exhibit 22: Non-therapeutic - Market size and forecast 2019-2024 ($ billions)
  • Exhibit 23: Non-therapeutic - Year-over-year growth 2020-2024 (%)
  • Exhibit 24: Market opportunity by type
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2019-2024 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2019-2024 ($ billions)
  • Exhibit 29: North America - Year-over-year growth 2020-2024 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2019-2024 ($ billions)
  • Exhibit 32: Europe - Year-over-year growth 2020-2024 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2019-2024 ($ billions)
  • Exhibit 35: Asia - Year-over-year growth 2020-2024 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2019-2024 ($ billions)
  • Exhibit 38: ROW - Year-over-year growth 2020-2024 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Ambulatory surgery procedures and visits to hospitals and ambulatory surgery centers in the US, 2010
  • Exhibit 43: Impact of drivers and challenges
  • Exhibit 44: Vendor landscape
  • Exhibit 45: Landscape disruption
  • Exhibit 46: Vendors covered
  • Exhibit 47: Vendor classification
  • Exhibit 48: Market positioning of vendors
  • Exhibit 49: 3M Co. - Vendor overview
  • Exhibit 50: 3M Co. - Business segments
  • Exhibit 51: 3M Co. - Organizational developments
  • Exhibit 52: 3M Co. - Geographic focus
  • Exhibit 53: 3M Co. - Segment focus
  • Exhibit 54: 3M Co. - Key offerings
  • Exhibit 55: Astellas Pharma Inc. - Vendor overview
  • Exhibit 56: Astellas Pharma Inc. - Business segments
  • Exhibit 57: Astellas Pharma Inc. - Organizational developments
  • Exhibit 58: Astellas Pharma Inc. - Geographic focus
  • Exhibit 59: Astellas Pharma Inc. - Key offerings
  • Exhibit 60: Cantel Medical Corp. - Vendor overview
  • Exhibit 61: Cantel Medical Corp. - Business segments
  • Exhibit 62: Cantel Medical Corp. - Organizational developments
  • Exhibit 63: Cantel Medical Corp. - Geographic focus
  • Exhibit 64: Cantel Medical Corp. - Segment focus
  • Exhibit 65: Cantel Medical Corp. - Key offerings
  • Exhibit 66: Ecolab Inc. - Vendor overview
  • Exhibit 67: Ecolab Inc. - Business segments
  • Exhibit 68: Ecolab Inc. - Organizational developments
  • Exhibit 69: Ecolab Inc. - Geographic focus
  • Exhibit 70: Ecolab Inc. - Segment focus
  • Exhibit 71: Ecolab Inc. - Key offerings
  • Exhibit 72: Getinge AB - Vendor overview
  • Exhibit 73: Getinge AB - Business segments
  • Exhibit 74: Getinge AB - Organizational developments
  • Exhibit 75: Getinge AB - Geographic focus
  • Exhibit 76: Getinge AB - Segment focus
  • Exhibit 77: Getinge AB - Key offerings
  • Exhibit 78: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 79: GlaxoSmithKline Plc - Business segments
  • Exhibit 80: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 81: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 82: GlaxoSmithKline Plc - Segment focus
  • Exhibit 83: GlaxoSmithKline Plc - Key offerings
  • Exhibit 84: Merck & Co. Inc. - Vendor overview
  • Exhibit 85: Merck & Co. Inc. - Business segments
  • Exhibit 86: Merck & Co. Inc. - Organizational developments
  • Exhibit 87: Merck & Co. Inc. - Geographic focus
  • Exhibit 88: Merck & Co. Inc. - Segment focus
  • Exhibit 89: Merck & Co. Inc. - Key offerings
  • Exhibit 90: Mylan NV - Vendor overview
  • Exhibit 91: Mylan NV - Product segments
  • Exhibit 92: Mylan NV - Organizational developments
  • Exhibit 93: Mylan NV - Geographic focus
  • Exhibit 94: Mylan NV - Segment focus
  • Exhibit 95: Mylan NV - Key offerings
  • Exhibit 96: Pfizer Inc. - Vendor overview
  • Exhibit 97: Pfizer Inc. - Business segments
  • Exhibit 98: Pfizer Inc. - Organizational developments
  • Exhibit 99: Pfizer Inc. - Geographic focus
  • Exhibit 100: Pfizer Inc. - Segment focus
  • Exhibit 101: Pfizer Inc. - Key offerings
  • Exhibit 102: Sanofi - Vendor overview
  • Exhibit 103: Sanofi - Business segments
  • Exhibit 104: Sanofi - Organizational developments
  • Exhibit 105: Sanofi - Geographic focus
  • Exhibit 106: Sanofi - Segment focus
  • Exhibit 107: Sanofi - Key offerings
  • Exhibit 108: Validation techniques employed for market sizing
  • Exhibit 109: Definition of market positioning of vendors
目次
Product Code: IRTNTR40140

About this market

Technavio's infection control market analysis considers sales from both therapeutic and non-therapeutic types. Our study also finds the sales of infection control in Asia, Europe, North America, and ROW. In 2019, the therapeutic segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as anti-infectives, such as antibiotics, anti-fungal drugs, and anti-viral drugs, which are used for the prevention and treatment of various infectious diseases will play a significant role in the therapeutic segment to maintain its market position. Also, our global infection control market report looks at factors such as strong incidence of HAIs, increasing number of surgical procedures worldwide, and growing geriatric population. However, concerns regarding the safety of reprocessed instruments, non-compliance toward anti-infective therapy, and complexities involved in storage and transportation of infection control therapeutics may hamper the growth of the infection control industry over the forecast period.

Overview

Growing geriatric population

The geriatric population is highly susceptible to infectious diseases. The incidence depends on the site of infection and location of the patient, whether a hospital, nursing home or community. Patients residing in nursing homes are mostly affected by pressure ulcer infections, urinary tract infection, and pneumonia. In addition, the chances of acquiring nosocomial infections are high among hospitalized elderly patients. Thus, the growth in the geriatric population will lead to the expansion of the global infection control market at a CAGR of over 4% during the forecast period.

Technological advances in sterilizing equipment

The global infection control market is currently witnessing an increasing interest of vendors to develop effective measures as infection control solutions. Vendors are increasingly exhibiting interest in developing effective measures as infection control solutions. Ultraviolet germicidal irradiation inactivates the pathogen by targeting their nucleic acids. The UV radiation is effective against all forms of pathogens, including bacteria, viruses, and fungi, and it has found widespread use in disinfecting surfaces, water, and air. The infection control systems that are based on these technologies, when used with appropriate care and protocols, can help reduce the incidences of HAIs and the health burden and economic costs associated with them. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global infection control market during the forecast period 2020-2024, view our report.

Competitive Landscape

With the presence of several major players, the global infection control market is moderately fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading infection control manufacturers, that include 3M Co., Astellas Pharma Inc., Cantel Medical Corp., Ecolab Inc., Getinge AB, GlaxoSmithKline Plc, Merck & Co. Inc., Mylan NV, Pfizer Inc., and Sanofi.

Also, the infection control market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
  • Value chain analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market Outlook

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Therapeutic - Market size and forecast 2019-2024
  • Non-therapeutic - Market size and forecast 2019-2024
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Technological advances in sterilization equipment
  • Rising awareness about infectious diseases
  • Growing risk of spreading infections via blood transfusions

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • 3M Co.
  • Astellas Pharma Inc.
  • Cantel Medical Corp.
  • Ecolab Inc.
  • Getinge AB
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Mylan NV
  • Pfizer Inc.
  • Sanofi

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO